Xencor, Inc. a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, announced the...
Back-to-back Presidential Symposium presentations of ENHERTU from DESTINY-Breast11 and DESTINY-Breast05 demonstrate its potential to become a foundat...
Presidential Symposium will feature DESTINY-Breast11 and DESTINY-Breast05, underscoring potential of ENHERTU® (fam-trastuzumab deruxtecan-nxki) in ...
To equip users with a complete next generation sequencing (NGS) solution from sample to answer, global genomics leader Integrated DNA Technologies (IDT),...
-Redefining Allergy Treatment with New Class of Trifunctional ECRIs designed to deliver powerful efficacy, rapid relief and complete control of alle...
Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patien...
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage spec...
ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosin...
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-0...
Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO) and InnoCare Pharma Limited (&ldqu...
- First subject received unilateral administration of NRTX-1001 in a new non-MTS cohort; no significant surgical complications or adverse events re...
MannKind Corporation (Nasdaq: MNKD) successfully completed the previously announced acquisition of scPharmaceuticals Inc. The acquisition of scPhar...
OXB acquires Resilience’s site in North Carolina, an FDA-approved, commercial-scale viral vector manufacturing facility In line with OXB’...
Industry report measures progress in six main areas: supply chain resilience, talent pool, R&D ecosystem, manufacturing agility, government polic...
© 2025 Biopharma Boardroom. All Rights Reserved.
